Intraday Price Movement and Volatility
On 24 Nov 2025, Indo US Bio-Tech experienced notable price fluctuations, with the stock touching an intraday high of Rs.134.75, representing a 6.77% rise from the previous close. However, the session closed near the day’s low at Rs.117.8, a 6.66% decline, signalling a sharp reversal during the trading day. The weighted average price volatility stood at 10.47%, underscoring the heightened uncertainty among traders and investors.
The stock’s performance lagged behind the Other Agricultural Products sector, underperforming by 6.22% on the day. This contrasts with the broader market trend, where the Sensex opened higher at 85,320.04 points, gaining 0.1% initially and trading near 85,254.79 points by midday, just 0.64% shy of its 52-week high of 85,801.70. The Sensex’s upward momentum was supported by mega-cap stocks and a bullish alignment of its 50-day and 200-day moving averages.
Technical Indicators Signal Weakness
Indo US Bio-Tech is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning often reflects sustained downward pressure and a lack of short-term buying interest. The stock’s 52-week high stands at Rs.386, highlighting the extent of the decline over the past year.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Financial Performance Highlights
Recent quarterly results indicate subdued profitability metrics for Indo US Bio-Tech. The Profit After Tax (PAT) for the quarter stood at Rs.3.45 crores, reflecting a 22.4% decline compared to the previous four-quarter average. Earnings before depreciation, interest, and taxes (PBDIT) reached Rs.4.17 crores, marking the lowest level recorded in recent quarters. The operating profit to net sales ratio also contracted to 13.52%, signalling tighter margins.
Over the past year, the stock’s price performance has been notably weak, with a total return of -53.48%. This contrasts sharply with the Sensex’s 7.75% gain and the BSE500’s 6.46% return over the same period. Despite the stock’s price decline, the company’s profits have shown a rise of 43.9% over the last year, indicating a divergence between earnings growth and market valuation.
Balance Sheet and Efficiency Metrics
Indo US Bio-Tech demonstrates a strong return on capital employed (ROCE) of 27.98%, reflecting efficient utilisation of capital resources. The company’s debt servicing capacity appears robust, with a Debt to EBITDA ratio of 0.91 times, suggesting manageable leverage levels. Net sales have grown at an annual rate of 31.50%, indicating healthy top-line expansion despite recent stock price pressures.
The valuation metrics show the company trading at an enterprise value to capital employed ratio of 2.5, which is considered attractive relative to peer averages. The price-to-earnings-to-growth (PEG) ratio stands at 0.3, highlighting a low valuation in relation to earnings growth. Promoters remain the majority shareholders, maintaining significant control over the company’s strategic direction.
Is Indo US Bio-Tech your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Market Context and Sector Overview
The Other Agricultural Products sector, to which Indo US Bio-Tech belongs, has experienced mixed performance in recent months. While the broader market indices have shown resilience, Indo US Bio-Tech’s stock has not mirrored this trend. The sector’s dynamics, combined with company-specific financial results, have contributed to the stock’s current valuation levels.
Despite the Sensex’s three-week consecutive rise and its position above key moving averages, Indo US Bio-Tech’s share price has not aligned with this positive market momentum. The divergence between the company’s earnings growth and stock price performance suggests that market participants are weighing other factors in their assessment.
Summary of Key Price and Performance Data
To summarise, Indo US Bio-Tech’s stock price reached Rs.117.8 today, marking a new 52-week low. The stock’s intraday volatility of 10.47% reflects significant price swings within the session. Over the past year, the stock has generated a negative return of 53.48%, contrasting with the Sensex’s positive performance. Financial metrics reveal a decline in quarterly profitability and operating margins, while efficiency and leverage ratios remain favourable.
The stock’s technical indicators, including trading below all major moving averages, reinforce the current downward trend. Meanwhile, the company’s fundamentals show a complex picture of profit growth amid valuation pressures.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
